Hyperion Therapeutics Inc (NASDAQ:HPTX)

46.06
Delayed Data
As of Apr 17
 +0.16 / +0.35%
Today’s Change
20.23
Today|||52-Week Range
46.96
+91.92%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$956.9M

Company Description

Hyperion Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat disorders in orphan diseases and hepatology. Its product, Ravicti is designed to lower ammonia in blood and for the treatment of urea cycle disorders and hepatic encephalopathy. The company was founded by Mark Blumling and Chris E. Rivera on November 1, 2006 and is headquartered in Brisbane, CA.

Contact Information

Hyperion Therapeutics, Inc.
2000 Sierra Point Parkway
Brisbane California 94005
P:(650) 745-7802
Investor Relations:
(650) 745-7829

Employees

Shareholders

Individual stakeholders50.23%
Mutual fund holders27.96%
Other institutional19.79%

Top Executives

Donald J. SantelPresident, Chief Executive Officer & Director
Jeffrey S. FarrowChief Financial Officer & Senior Vice President
Bruce F. ScharschmidtChief Medical Officer & Senior Vice President
Dion F. CoakleyGlobal Vice President-Clinical Operations
Christine A. NashChief Commercial Officer & Senior Vice President

To view my watchlist

Not a member yet?

Sign up now for a free account